Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03646292
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:46.543302+00:00
Published At
2025-03-05T00:00:00+00:00
Record Updated At
2025-03-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease", "Type 2 Diabetes", "Digestive System Disease", "Liver Diseases", "Fatty Liver", "Metabolic Dysfunction-Associated Steatotic Liver Disease", "Non-Alcoholic Fatty Liver Disease", "Hypoglycemic Agents", "Physiological Effects of Drugs", "Sodium-Glucose Cotransporter 2 Inhibitors", "Pioglitazone", "Molecular Mechanisms of Pharmacological Action", "Empagliflozin", "Thiazolidinediones"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-05"
protocolSection.identificationModule.nctId
"NCT03646292"
protocolSection.identificationModule.officialTitle
"Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease (protocolSection.conditionsModule.conditions)
  • Type 2 Diabetes (protocolSection.conditionsModule.conditions)
  • Digestive System Disease (protocolSection.conditionsModule.conditions)
  • Liver Diseases (protocolSection.conditionsModule.conditions)
  • Fatty Liver (protocolSection.conditionsModule.conditions)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (protocolSection.conditionsModule.conditions)
  • Non-Alcoholic Fatty Liver Disease (protocolSection.conditionsModule.conditions)
  • Hypoglycemic Agents (protocolSection.conditionsModule.conditions)
  • Physiological Effects of Drugs (protocolSection.conditionsModule.conditions)
  • Sodium-Glucose Cotransporter 2 Inhibitors (protocolSection.conditionsModule.conditions)
  • Pioglitazone (protocolSection.conditionsModule.conditions)
  • Molecular Mechanisms of Pharmacological Action (protocolSection.conditionsModule.conditions)
  • Empagliflozin (protocolSection.conditionsModule.conditions)
  • Thiazolidinediones (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.